Drug
Sonelokimab
Sonelokimab: highest development phase Phase 3, developed by MoonLake Immunotherapeutics AG. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- MoonLake Immunotherapeutics AG
Trials
| Drug | Phase | Indication |
|---|---|---|
| Sonelokimab NCT07223138 | Phase 3 | Arthritis, Psoriatic |
Latest
No recent events.
Follow Sonelokimab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.